TELA Bio is trying to win surgeons over with a tissue-repair product designed to work with the body, while rapidly expanding its sales reach in the U.S. and Europe. The upside depends on whether that wider footprint and growing clinical support can translate into faster adoption and a clear path toward breaking even, despite signs that growth is already slowing.Read more
TELA Bio bets that surgeons will increasingly choose its reinforced tissue repair materials over traditional mesh as hospitals put more weight on long-term patient results. The upside hinges on broader use beyond niche cases and faster traction overseas, but the big question is whether the company can turn that momentum into sustainable profits before larger rivals squeeze it out.Read more
TELA Bio rides growing demand for soft tissue repair products used in hernia and reconstructive surgery, but bigger rivals and slow uptake in new regions could keep profits elusive. See what might help the company turn steady procedure growth into real momentum—and what could delay it.Read more
No trending discussion available.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
